Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.

Abstract:

BACKGROUND:The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP® for immunogenicity and safety in the course of clinical trial phase II on healthy subjects up to 60 years. METHODS:The trial involved 150 subjects in randomized 2:1 groups that received either RIBSP vaccine or comparator vaccine VAXIGRIP®. One dose (0.5 ml) of either vaccine contained 15 µg of hemagglutinin of each influenza virus strain recommended by WHO for the Northern hemisphere in 2016-2017 flu season. The observation period lasted 21 days. The trial was registered at ClinicalTrials.gov identifier NCT03016143. RESULTS:Assessment of immunogenic activity of the vaccine under study showed that in 21 days the portion of participants with 4-fold seroconversions was 80.0% to А/H1N1; 65.0% to А/H3N2 and 64.0% to B virus. Antibody titer increase factor in the group of subjects that received RIBSP vaccine was 13.4 for А/H1N1; 5.2 for А/H3N2 and 5.2 for B virus. The subjects that received RIBSP vaccine demonstrated 88% seroprotection rate against А/H1N1; 75% against А/H3N2 and 61% against B virus. In the course of evaluating the vaccine safety, no serious adverse events were recorded. All changes of laboratory data were slight and single in most cases. All recorded local reactions have been light in character and these have been predicted reactions observed at vaccination against influenza. CONCLUSION:Comparison vaccines RIBSP and VAXIGRIP®, showed similar immunogenic activity. The RIBSP vaccine is safe and immunogenic for the elderly and conforms to international criteria in CPMP/BWP/214/96.

journal_name

Hum Vaccin Immunother

authors

Sarsenbayeva G,Issagulov T,Kassenov M,Abitay R,Orynbayev M,Stukova M,Pisareva M,Davlyatshin T,Lespek K,Khairullin B

doi

10.1080/21645515.2019.1705691

subject

Has Abstract

pub_date

2020-08-02 00:00:00

pages

1791-1797

issue

8

eissn

2164-5515

issn

2164-554X

journal_volume

16

pub_type

杂志文章
  • Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.

    abstract::Individuals infected with human immunodeficiency virus (HIV) have excess risk of developing human papillomavirus (HPV)-related disease. A substantial fraction of HPV-associated cancers is caused by HPV serotypes not included in the currently available vaccines. Among healthy women, both Cervarix(®) (HPV-16/18, GlaxoSm...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/hv.27925

    authors: Toft L,Tolstrup M,Müller M,Sehr P,Bonde J,Storgaard M,Østergaard L,Søgaard OS

    更新日期:2014-01-01 00:00:00

  • Immunization of children with secondary immunodeficiency.

    abstract::The main causes of secondary immunodeficiency at a pediatric age include infectious diseases (mainly HIV infection), malignancies, haematopoietic stem cell or solid organ transplantation and autoimmune diseases. Children with secondary immunodeficiency have an increased risk of severe infectious diseases that could be...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1039208

    authors: Esposito S,Prada E,Lelii M,Castellazzi L

    更新日期:2015-01-01 00:00:00

  • Mixing of diphtheria, tetanus, and acellular pertussis (DTaP) vaccines in a population of children in managed care.

    abstract::The Advisory Committee on Immunization Practices recommends administering diphtheria, tetanus and acellular pertussis (DTaP) vaccines to children at 2, 4, 6, 15-18 months, and 4-6 y of age; preferably with the same-brand vaccine for the whole series. We estimated age-appropriate DTaP dose completion and the proportion...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/21645515.2014.985506

    authors: Masseria C,Buikema AR,Liu F,Krishnarajah G

    更新日期:2015-01-01 00:00:00

  • Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count.

    abstract::HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases than are healthy adults. Pneumococcal vaccination may be the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is still unclear. In this study, HIV-infected subjects aged ≥18 yea...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1643677

    authors: Song JY,Cheong HJ,Noh JY,Choi MJ,Yoon JG,Kim WJ

    更新日期:2020-01-01 00:00:00

  • Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism.

    abstract::Combined therapy using chemotherapeutic drugs and immunotherapeutics offers some promise for treating patients with cancer. In this study, we evaluated whether cisplatin delivered by intratumoral (IT)-electroporation (EP) might enhance antitumor activity against established B16 melanoma and whether further addition of...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.22346

    authors: Kim H,Sin JI

    更新日期:2012-11-01 00:00:00

  • The regulatory T cells in anti-influenza antibody response post influenza vaccination.

    abstract::The efficacy and effectiveness of influenza vaccines depend primarily on the vaccine recipient and the virus similarity to the endemic virus. Regulatory T cells (Tregs) and cytokines are known to restrict immune responses against viral infections. We conducted this study to explore the role of Tregs, cytokines, and an...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 临床试验,杂志文章

    doi:10.4161/hv.21117

    authors: Wang SM,Tsai MH,Lei HY,Wang JR,Liu CC

    更新日期:2012-09-01 00:00:00

  • Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013.

    abstract::Neisseria meningitidis or meningococcus is divided into 12 distinct serogroups of which A, B, C, W, X, and Y are medically most important and cause health problems in different parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. Globally, serogroup A has be...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1051276

    authors: Bröker M,Emonet S,Fazio C,Jacobsson S,Koliou M,Kuusi M,Pace D,Paragi M,Pysik A,Simões MJ,Skoczynska A,Stefanelli P,Toropainen M,Taha MK,Tzanakaki G

    更新日期:2015-01-01 00:00:00

  • Regional variations in HPV vaccination among 9-17 year old adolescent females from the BRFSS, 2008-2010.

    abstract::Human papillomavirus (HPV) vaccine uptake among 18-26 y old women varies by geographic region in the US. However, little is known about regional variations in vaccination among girls who are in the vaccine's targeted age groups. Regional variation in HPV vaccination among female adolescents (9-17 y old) was examined u...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/21645515.2014.980202

    authors: Hirth JM,Rahman M,Smith JS,Berenson AB

    更新日期:2014-01-01 00:00:00

  • Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.

    abstract::Post licensure surveillance of adverse events following immunization (AEFI) is a fundamental activity to improve safety and maintain public confidence in vaccines.   Since 2011, the Liguria Region has been involved in the inter-regional project of post-marketing surveillance of AEFI, coordinated by the Italian Medicin...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.34360

    authors: Alicino C,Merlano C,Zappettini S,Schiaffino S,Della Luna G,Accardo C,Gasparini R,Durando P,Icardi G

    更新日期:2015-01-01 00:00:00

  • Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy.

    abstract::The interleukin 6 (IL6) family of proteins regulate important cellular processes and act through a variety of signaling pathways via a shared gp130 receptor. In the liver, there is a large body of evidence showing a protective and pro-regenerative role for IL6 cis and trans signaling. While a few studies suggest a pat...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1761203

    authors: Widjaja AA,Chothani SP,Cook SA

    更新日期:2020-10-02 00:00:00

  • Timeliness of vaccination in infants followed by primary-care pediatricians in France.

    abstract::Vaccination status is more often evaluated by up-to-date vaccination coverage rather than timeliness of immunization. Delaying vaccination may be dangerous during infancy. The aim of this study was to identify the importance of potentially dangerous vaccination delay (previously defined) and determinants of these dela...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1409318

    authors: Bailly AC,Gras P,Lienhardt JF,Requillart JC,Vié-le-Sage F,Martinot A,Dubos F

    更新日期:2018-04-03 00:00:00

  • Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.

    abstract::The four-component meningococcal serogroup B vaccine (4CMenB) contains antigens present in the majority of meningococci causing invasive meningococcal disease (IMD) and may potentially offer protection against strains belonging to non-B serogroups. This study aimed to evaluate the ability of 4CMenB-induced antibodies ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1855951

    authors: Fazio C,Biolchi A,Neri A,Tomei S,Vacca P,Ambrosio L,Palmieri A,Mori E,La Gaetana R,Pizza M,Giuliani MM,Serino L,Stefanelli P

    更新日期:2021-01-31 00:00:00

  • Vaccination among Polish university students. Knowledge, beliefs and anti-vaccination attitudes.

    abstract::Anti-vaccination movement has existed as long as the vaccines themselves, but its mode of action and social influences evolved over time. Such attitude with no doubt has negative impact on vaccination rates and eradication of infectious diseases. In this study, we used an online survey to examine vaccination attitudes...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1365994

    authors: Zarobkiewicz MK,Zimecka A,Zuzak T,Cieślak D,Roliński J,Grywalska E

    更新日期:2017-11-02 00:00:00

  • Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines

    abstract::Prophylactic paracetamol administration impacts vaccine immune response; this study ( www.clinicaltrials.gov : NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/21645515.2016.1223001

    authors: Falup-Pecurariu O,Man SC,Neamtu ML,Chicin G,Baciu G,Pitic C,Cara AC,Neculau AE,Burlea M,Brinza IL,Schnell CN,Sas V,Lupu VV,François N,Swinnen K,Borys D

    更新日期:2017-03-04 00:00:00

  • Titering of 2009 pandemic H1N1 influenza virus hemagglutinin inhibition antibody in nonvaccinated pregnant women in Shiraz, Southern Iran.

    abstract::Influenza may cause severe complications for pregnant women. In this study antibody response against 2009 H1N1 influenza virus in pregnant women was investigated. This seroprevalance cross sectional and questionnaire based study was conducted using a convenient sampling method. Blood samples of pregnant women were che...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.19189

    authors: Honarvar B,Moghadami M,Moattari A,Emami A,Tabatabaee HR,Jahromi BN,Asadi N,Mousavizadeh A,Lankarani KB,Joulaei H,Ghaffarpasand F

    更新日期:2012-05-01 00:00:00

  • Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next.

    abstract::The practice of passive immunization with human immune globulin (IG) for the control of communicable diseases (measles, rubella and hepatitis A) differs somewhat between Australia, the United States of America, the United Kingdom, and New Zealand despite the many similarities of these countries, including disease inci...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.25311

    authors: Young MK,Cripps AW

    更新日期:2013-09-01 00:00:00

  • ASVAC2019: 7th Asian Vaccine Conference.

    abstract::The 7th Asian Vaccine Conference (ASVAC 2019) was held in Yangon, Myanmar from 13 to 15, September 2019. It brought together stakeholders in the field of vaccination to address challenges and issues relevant to clinical practice and immunization programs in the region. The conference themed "Immunization: sustaining h...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1695460

    authors: Linn K,Bravo L,Goh DYT,Nelson EAS

    更新日期:2020-07-02 00:00:00

  • A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

    abstract::The present study evaluated the safety and immunogenicity of the 2013/2014 trivalent surface antigen inactivated subunit seasonal influenza virus vaccine Fluvirin® in healthy adults (18 - ≤ 60 years) and elderly (>60 years). The vaccine contained 15 µg haemagglutinin protein from each of influenza A/California/7/2009 ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1064570

    authors: Roggelin L,Vinnemeier CD,Meyer S,Witte K,Marx L,Theeß W,Burchard GD,Rolling T,Cramer JP

    更新日期:2015-01-01 00:00:00

  • Plasmodium falciparum gametocyte transit through the cutaneous microvasculature: A new target for malaria transmission blocking vaccines?

    abstract::Malaria remains one of the most significant infectious diseases worldwide. Concordant with scaled intervention efforts and the emphasis of elimination and eradication on the agenda of many malaria control programs, the development of a malaria vaccine that reduces transmission of the parasite from human host to mosqui...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1183076

    authors: Nixon CP

    更新日期:2016-12-01 00:00:00

  • Prevalence and genotype distribution of human papillomavirus among women with cervical lesions in Shenzhen city, China.

    abstract::There is currently a lack of sufficient data on human papillomavirus (HPV)-attributable cervical carcinoma in China. Accordingly, we aimed to determine the prevalence and genotype distribution of HPV among women with cervical lesions in Shenzhen, in order to evaluate the potential benefit of HPV vaccination programs a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1805993

    authors: Mai Q,Yang X,Cheng H,Wu G,Wu Z

    更新日期:2020-09-22 00:00:00

  • Evaluating impact of school outreach vaccination programme in Hong Kong influenza season 2018 - 2019.

    abstract::School-based vaccination, as a means to mitigate seasonal influenza outbreak, depends on attaining adequate coverage rate. We evaluated the potential of a fully subsidized school outreach vaccination (SOV) program to achieve epidemic prevention potential in Hong Kong. The purpose of this study was to evaluate the impa...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1678357

    authors: Lau YL,Wong WHS,Hattangdi-Haridas SR,Chow CB

    更新日期:2020-04-02 00:00:00

  • Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.

    abstract:UNLABELLED:In adults with a tetanus-prone injury, combined vaccines such as Tdap-IPV (REPEVAX®) can boost immunity against several diseases simultaneously. This Phase IIIb, parallel-group, open-label trial compared antibody responses to Tdap-IPV and tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.4161/hv.22083

    authors: Laurichesse H,Zimmermann U,Galtier F,Launay O,Duval X,Richard P,Sadorge C,Soubeyrand B

    更新日期:2012-12-01 00:00:00

  • Anti-leukemia T cells in AML: TNF-α⁺ CD8⁺ T cells may escape detection and possibly reflect a stage of functional impairment.

    abstract::Leukemia-associated antigens such as proteinase-3 (PR3) and Wilms' tumor protein-1 (WT-1) are potential targets of T-cell responses, which can be monitored by T-cell assays within vaccination trials and after allogeneic stem cell transplantation (SCT). In chronic myeloid leukemia (CML) an aberrant cytokine profile of ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.24250

    authors: Flörcken A,van Lessen A,Terwey TH,Dörken B,Arnold R,Pezzutto A,Westermann J

    更新日期:2013-06-01 00:00:00

  • Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.

    abstract::Cancer progression depends on stepwise accumulation of oncogenic mutations and a select group of growth factors essential for tumor growth, metastasis and angiogenesis. Agents blocking the epidermal growth factor receptor (EGFR, also called HER1 and ERBB1) and the co-receptor called HER2/ERBB2 have been approved over ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1102809

    authors: Gaborit N,Lindzen M,Yarden Y

    更新日期:2016-03-03 00:00:00

  • Maternal and infant outcomes among women vaccinated against pertussis during pregnancy.

    abstract::Tetanus, diphtheria, and acellular pertussis (Tdap) vaccination is recommended for all women during each pregnancy to prevent pertussis in young infants. However, data on the safety of this protective measure are limited and conflicting. To assess maternal and infant outcomes associated with administration of this vac...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2016.1157241

    authors: Berenson AB,Hirth JM,Rahman M,Laz TH,Rupp RE,Sarpong KO

    更新日期:2016-08-02 00:00:00

  • EV71 vaccination impact on the incidence of encephalitis in patients with hand, foot and mouth disease.

    abstract::In order to analyze the effect of EV71 vaccination on the incidence of encephalitis in patients with HFMD, 292 cases were vaccinated, and 2,486 cases were not vaccinated which were collected in 2018 and 2019. It shows that the incidence rate of encephalitis in vaccinated patients was significantly lower than that in n...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1851129

    authors: Li J,Yin X,Lin A,Nie X,Liu L,Liu S,Li N,Wang P,Song S,Wang S,Xu D

    更新日期:2021-01-31 00:00:00

  • Overview of the cancer vaccine field: are we moving forward?

    abstract::Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is a first in a series dedicated to evaluate the status of current global clinical pipeline for cancer vaccines. Apart from specific areas of medical need which can be addressed by cancer vaccines, the a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.20474

    authors: Kudrin A,Hanna MG Jr

    更新日期:2012-08-01 00:00:00

  • Dissecting the indirect effects caused by vaccines into the basic elements.

    abstract::Vaccination directly protects vaccinated individuals, but it also has the potential for indirectly protecting the unvaccinated in a population (herd protection). Unintended negative consequences such as the re-manifestation of infection, mainly expressed as age shifts, result from vaccination programs as well. We disc...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1052196

    authors: Scarbrough Lefebvre CD,Terlinden A,Standaert B

    更新日期:2015-01-01 00:00:00

  • Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines.

    abstract::Vaginal and vulvar cancers do not account for a large proportion of gynecologic malignancies but their impact is significant. Both vaginal and vulvar lesions have precursors and display levels of dysplasia before progression to invasive disease. Human Papillomavirus (HPV) is a known causative agent of such dysplasia a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1147634

    authors: Buchanan TR,Graybill WS,Pierce JY

    更新日期:2016-06-02 00:00:00

  • The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind,

    abstract::We aimed to determine the efficacy of the 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in children aged 18-months to <18-years with recurrent protracted bacterial bronchitis (rPBB), chronic suppurative lung disease (CSLD) or bronchiectasis. In a multi-centre, double-blind randomi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1488562

    authors: O'Grady KF,Chang AB,Cripps A,Mulholland EK,Smith-Vaughan H,Wood N,Danchin M,Thornton R,Wilson A,Torzillo PJ,Morris PM,Richmond P,Rablin S,Arnold D,Connor A,Goyal V,Stoney T,Perrett K,Grimwood K

    更新日期:2018-01-01 00:00:00